Charles River Stock Hits 52-Week High - Here's Why - Charles River (NYSE:CRL)
Charles River Laboratories (CRL) raised its fiscal 2026 adjusted EPS outlook to $11.15 to $11.45 from $10.80 to $11.30, and lifted revenue guidance to $3.879 billion to $3.920 billion. Q2 adjusted EPS was $3.02 vs $2.74 consensus. Net bookings rose to $701 million and DSA backlog to $1.97 billion. CRL shares hit a 52-week high.
How this was made
The 30-second read
Why it matters
Raised 2026 guidance alongside a Q2 adjusted EPS beat and stronger bookings/book-to-bill suggests demand improvement, but segment declines (RMS, Manufacturing Solutions) and guidance for RMS organic decline temper the outlook.
Market read
Traders can update 2026 estimate models immediately based on the raised EPS and revenue ranges, and monitor whether DSA strength continues to offset RMS pressure.
What to watch
The article notes flat NIH budgets and slower grant processing as drivers of RMS weakness; if these persist, upside from DSA may not fully offset segment declines.
Background
Charles River is a life-science services provider with segments including Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing Solutions.
Ticker impact
Charles River raised fiscal 2026 adjusted EPS to $11.15-$11.45 and revenue to $3.879B-$3.920B after Q2 results beat consensus.
Near-term positive drift as traders reprice 2026 estimates; follow-through depends on RMS weakness offset.
The article discloses multiple fresh, company-specific datapoints: raised EPS and revenue outlook, Q2 adjusted EPS beat, higher net bookings and book-to-bill, and segment demand commentary.
Market effects
Signals improving demand in regulated safety assessment services, while research models remain pressured, highlighting uneven life-science services demand.
No explicit regional macro impact beyond North America weakness and China offset in RMS.
Improving IND-enabling study demand suggests broader global biopharma workflow normalization, but segment mix matters.
Counterpoint
RMS and Manufacturing Solutions remain down year over year, so the raised consolidated outlook may be more dependent on DSA strength than broad-based recovery.
Key entities
- companyCharles River Laboratories
Raised fiscal 2026 adjusted earnings outlook and revenue forecast; reported Q2 beat and segment-level demand trends.
